Marker Therapeutics Form 3 shows zero holdings for director

Rhea-AI Filing Summary

Marker Therapeutics (MRKR) filed a Form 3 reporting the initial beneficial ownership for a director as of 10/31/2025. The filing states that no securities are beneficially owned.

The form was signed by /s/ Julio C. Esquivel as attorney-in-fact for Kathryn Penkus Corzo, pursuant to a power of attorney dated October 15, 2025.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Corzo Kathryn Penkus

(Last) (First) (Middle)

MARKER THERAPEUTICS, INC.

2450 HOLCOMBE BLVD, TMC PARTNERS OFFICE

(Street)

HOUSTON TX 77021

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/31/2025

3. Issuer Name and Ticker or Trading Symbol
Marker Therapeutics, Inc. [ MRKR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Mr. Julio C. Esquivel is signing as Attorney-in-Fact pursuant to power of attorney dated October 15, 2025, granted by the Reporting Person, a copy of which is filed as an exhibit and incorporated herein by reference.

No securities are beneficially owned.

	/s/ Julio C. Esquivel as Attorney-In-Fact for Kathryn Penkus Corzo	11/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Marker Therapeutics (MRKR) file?

A Form 3, the initial statement of beneficial ownership for a reporting person.

Who is the reporting person on the MRKR Form 3?

The form pertains to a director; it was signed by /s/ Julio C. Esquivel as attorney-in-fact for Kathryn Penkus Corzo.

What is the event date on the MRKR Form 3?

The event date is 10/31/2025.

How many MRKR securities are reported as beneficially owned?

The filing states no securities are beneficially owned.

Who signed the MRKR Form 3 and under what authority?

It was signed by /s/ Julio C. Esquivel as attorney-in-fact under a power of attorney dated October 15, 2025.

What is the reporting person’s relationship to Marker Therapeutics?

The reporting person is a director.